Leveraging AI to Accelerate Medical Data Cleaning: A Comparative Study of AI-Assisted vs. Traditional Methods

Abstract

Clinical trial data cleaning represents a critical bottleneck in drug development, with manual review processes struggling to manage exponentially increasing data volumes and complexity. This paper presents Octozi, an artificial intelligence-assisted platform that combines large language models with domain-specific heuristics to transform medical data review. In a controlled experimental study with experienced medical reviewers (n=10), we demonstrate that AI assistance increased data cleaning throughput by 6.03-fold while simultaneously decreasing cleaning errors from 54.67% to 8.48% (a 6.44-fold improvement). Crucially, the system reduced false positive queries by 15.48-fold, minimizing unnecessary site burden. Economic analysis of a representative Phase III oncology trial reveals potential cost savings of 5.1 million, primarily driven by accelerated database lock timelines (5-day reduction saving 4.4M), improved medical review efficiency (420K savings), and reduced query management burden (288K savings). These improvements were consistent across reviewers regardless of experience level, suggesting broad applicability. Our findings indicate that AI-assisted approaches can address fundamental inefficiencies in clinical trial operations, potentially accelerating drug development timelines such as database lock by 33% while maintaining regulatory compliance and significantly reducing operational costs. This work establishes a framework for integrating AI into safety-critical clinical workflows and demonstrates the transformative potential of human-AI collaboration in pharmaceutical clinical trials.

0

Turn this paper into a full lesson

ArcXiv compiles a staged curriculum from this paper: 8-12 lessons across beginner → advanced, synthesised section guides, visuals, flashcards, a quiz, exercises, and on-demand deep dives per section. Grounded in the abstract, never invented.

Discussion (0)

Sign in to join the discussion.

Loading comments…